V. K B Prabhakar, J. R E Davis

    Research output: Contribution to journalArticlepeer-review


    Hyperprolactinaemia is a frequent cause of reproductive problems encountered in clinical practice. A variety of pathophysiological conditions can lead to hyperprolactinaemia; therefore, pregnancy, drug effects, hypothyroidism and polycystic ovary syndrome should be excluded before investigating for prolactin-secreting pituitary tumours. Prolactinomas are mainly diagnosed in women aged 20-40 years. They present with clinical features of hyperprolactinaemia (galactorrhoea, gonadal dysfunction), and more rarely with large tumours, headache and visual field loss due to optic chiasm compression. Medical therapy with dopamine agonists is the treatment of choice for both micro- and macroprolactinomas. Tumour shrinkage and restoration of gonadal function are achieved in the majority of cases with dopamine agonists. A trial of withdrawal of medical therapy may be considered in many patients with close follow-up. Pituitary surgery and radiotherapy currently have very limited indications. Pregnancies in patients with prolactinomas need careful planning and close monitoring. © 2007 Elsevier Ltd. All rights reserved.
    Original languageEnglish
    Pages (from-to)341-353
    Number of pages12
    JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
    Issue number2
    Publication statusPublished - Apr 2008


    • dopamine agonists
    • hyperprolactinaemia
    • pituitary
    • prolactin
    • prolactinomas


    Dive into the research topics of 'Hyperprolactinaemia'. Together they form a unique fingerprint.

    Cite this